RaySearch and Mevion Medical Systems are extending their collaboration agreement to support the RayCare oncology information system (OIS), which is currently in development at RaySearch, and to take full advantage of the advanced treatment capabilities of the MEVION S250i with HYPERSCAN with Adaptive Aperture.
The agreement was announced at the 58th annual meeting of the American Society for Radiation Oncology (ASTRO) in Boston.
RayCare is the next-generation OIS, developed from the ground up by RaySearch to support the complex logistical challenges in modern, large-scale radiation therapy centers.
RayCare integrates the high-performance radiation therapy algorithms available in RayStation® and adds advanced features for clinical resource optimization, workflow automation and adaptive radiation therapy. The system is expected to be released in 2017.
Adaptive Aperture is a proprietary low-profile micro-multileaf collimator system designed specifically for HYPERSCAN pencil beam scanning. Its unique layer-by-layer beam collimation and blocking achieves unprecedented one to three millimeter collimated spot sizes, for all energies, at any depth.
Under the agreement, RaySearch will develop planning capabilities to support the layer-by-layer collimation of Adaptive Aperture.
Previous collaboration between RaySearch and Mevion has led to impressive results at Mevion customer sites, such as Ackerman Cancer Center (ACC) in Jacksonville, Florida.
ACC commissioned RayStation for its MEVION S250 in just two weeks, achieving the fastest clinical ramp-up in proton therapy history. The center is now treating more than 40 patients per day in a single proton therapy room.
Townsend Zwart, Senior Director of Advanced Development at Mevion Medical Systems, says, “Adaptive Aperture is ideal for intensity modulated proton therapy (IMPT) because it creates the sharpest penumbra physically achievable without the need for manual apertures and adjustments. We are excited to extend our relationship with RaySearch to help radiation oncologists make the most of this advanced technology.”
Johan Löf, CEO of RaySearch, says, “Partnering with Mevion, the market leader in compact proton therapy systems, enables us to provide cancer centers with a complete turnkey solution to deliver the world’s most advanced proton therapy treatment.”